### Common Drug Review *

**Submission Status**

**Product:** Cipralex  
**Generic Name:** escitalopram oxalate  
**Manufacturer:** Lundbeck Canada Inc.  

**Submission Type:** Resubmission  

**Date Submission Received:** 2006-Jun-08  
**Date NOC Issued:** 2006-Mar-01  
**Targeted CEDAC Meeting:** 2006-Oct-18  
**Priority Review Granted:** Not Requested  

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date**</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
</table>
Additional requirements requested June 19, 2006. Additional requirements received June 22, 2006.  
**  
| 2     | CDR Reviewers' Reports Completed  
• Reviewers selected and contracted  
• Literature search and selection completed  
• Systematic review of clinical data completed  
• Critical appraisal of pharmacoeconomic (PE) data completed  
• Clinical and PE reports written  
• Reports edited and finalized  
• Reviewers' reports sent to manufacturer | 45            | 2006-Aug-28     | 2006-Aug-29  
**  
| 3     | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7             | 2006-Sep-07     | 2006-Sep-08  
Due date for manufacturer's comments September 8, 2006.  
**  
| 4     | Reviewers' Reply to Manufacturer's Comments Completed | 7             | 2006-Sep-18     | 2006-Sep-12  
**  
| 5     | CEDAC Brief Completed and Sent to CEDAC Members | 5             | 2006-Oct-03     | 2006-Oct-03  
**  
**  
Request for extension of Embargo Period received on November 1, 2006. Extension granted, new end date for embargo period is December 6, 2006.  
**  
| 8     | Embargo Period***  
Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation | 10            | 2006-Nov-08     | 2006-Dec-06  
Request for Reconsideration received December 6, 2006.  
**  
| 9 (a) | Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) | 5             |                |  
**  
| 9 (b) | Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(Clarification Requested, no Request for Reconsideration made) | 5             |                |  
**  
| 9 (c) | Placed on CEDAC Agenda For Reconsideration  
(At Manufacturer's request)  
| 25 Depends on Meeting Dates | 2007-Jan-17 | 2007-Jan-17  
**  
| 10    | Final Recommendation sent to Drug Plans, ACP, and Manufacturer | 5             | 2007-Jan-24     | 2007-Jan-24  
Notice of Final Recommendation issued.  
**  

---

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.  
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).  
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.